SCHEDULE: Lynx1 Withdraws Neuphoria Bid Amid 'Reckless' Dilution

Lynx1 Capital Management has withdrawn its $5.20 per share acquisition offer for Neuphoria Therapeutics, citing 'reckless' share issuances and significant shareholder dilution.

Summary

• Lynx1 Capital Management LP and Weston Nichols (the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13D.
• The Reporting Persons delivered a letter to Neuphoria Therapeutics Inc.'s Board of Directors on November 18, 2025, to withdraw their non-binding proposal to acquire all outstanding shares for $5.20 per share in cash.
• The withdrawal is attributed to the Board's actions which have 'dramatically altered' the Company's capital structure and balance sheet, making it impossible to recalculate an appropriate bid.
• Lynx1 remains highly interested in acquiring Neuphoria or a select royalty asset, but not under the current circumstances.
• The Reporting Persons beneficially own 875,328 shares of common stock, representing 16.3% of the class.
• The reduction in Lynx1's percentage ownership is due to an increase in Neuphoria's outstanding shares, not a disposal of shares by Lynx1.
• Neuphoria's outstanding shares increased to 5,377,329 as of November 13, 2025, up from 2,357,613 as of September 30, 2025.
• Lynx1 has nominated Stephen Doberstein and Kimberly Smith for election to Neuphoria's Board of Directors.

Sentiment

Score: 2

Explanation: The filing conveys a strongly negative sentiment due to the withdrawal of a potential acquisition offer, severe shareholder dilution, and explicit accusations of 'reckless,' 'illogical,' 'irresponsible,' and 'value destructive' actions by the company's management and board. The criticism of corporate governance practices further contributes to the negative outlook.

Negatives

• Neuphoria's Board has engaged in a 'reckless share-issuance spree' under its at-the-market (ATM) offering program since October 20, 2025.
• The Company has issued over 3 million shares since October 20, 2025, increasing shares outstanding by more than 125% or 30% dilution per week.
• Shares were issued for average net proceeds of approximately $5 per share, which is less than the Company's cash value per share of $5.79 as of September 30, 2025.
• This share issuance is described as 'transferring value from existing shareholders to new investors at a discount' and 'value destructive'.
• It is considered 'illogical and counterproductive' for the Company to issue new equity while simultaneously running a strategic-alternatives process.
• The Board registered for an additional $20 million of common stock issuance, indicating an intent to continue diluting existing shareholders.
• The Board purportedly set October 15 as the record date for the upcoming annual meeting, disenfranchising over 55% of current shareholders who purchased shares after the AFFIRM-1 trial failure and subsequent dilution.
• Lynx1 views the Board's actions as 'illogical and irresponsible acts' and 'acts of entrenchment'.

Risks

• Significant shareholder dilution due to ongoing at-the-market (ATM) equity offerings.
• Potential for further value destruction if the Company continues to issue shares at depressed prices, especially below cash value per share.
• Risk of board entrenchment, as suggested by Lynx1 regarding the record date for the annual meeting.
• Uncertainty regarding the Company's strategic review process, which is being undermined by current financing activities.
• The failure of the AFFIRM-1 trial, which led to a significant stock price decline and initiated the current strategic review.

Future Outlook

Lynx1 Capital Management, despite withdrawing its current acquisition offer, states it remains highly interested in acquiring Neuphoria or a select royalty asset of the Company. However, it emphasizes that the 'value destructive issuances must cease' and calls for the Board to commit not to undertake further dilutive financing transactions prior to the annual meeting. The future outlook is uncertain given the ongoing dispute between Lynx1 and the Board regarding capital structure and corporate governance.

Management Comments

• "To be crystal clear—Lynx1 remains highly interested in acquiring Neuphoria or a select royalty asset of the Company."
• "While we remain committed to the economics of our November 10 proposal, it has become impossible to recalculate an appropriate bid for the Company in light of the ongoing transformation of the Company's balance sheet."
• "Since then, the Company has conducted a reckless share-issuance spree under its at-the-market (ATM) offering program."
• "Even worse, the Company has issued these shares for average net proceeds of approximately $5 per share, which is less than the Company’s cash value per share. This is tantamount to transferring value from existing shareholders to new investors at a discount."
• "Furthermore, it is illogical and counterproductive for the Company to issue new equity while simultaneously running a strategic-alternatives process."
• "These value destructive issuances must cease."
• "It appears that the Board intends to continue to dilute existing shareholders regardless of the consequences to them."
• "This behavior raises serious questions as to whether the Board is acting in the interest of all current shareholders."
• "Based on the Board’s continued illogical and irresponsible acts, which we consider to be acts of entrenchment, we believe it has become imperative to add truly independent, highly qualified directors to the Board in order to protect shareholder interests."
• "We call upon the Board to commit not to undertake any further dilutive financing transactions prior to the annual meeting and to reset the record date to ensure that all shareholders—not just a shrinking minority of them—have a meaningful voice in the composition of the Board."
• "We are prepared to take any and all actions we deem necessary to protect the shareholders of the Company."

Industry Context

This filing highlights a significant instance of shareholder activism within the biotechnology sector, a common occurrence for companies undergoing strategic reviews, especially after clinical trial failures. The use of at-the-market (ATM) offerings is a standard financing tool, but its deployment at prices below cash value per share and during a strategic review, as criticized by Lynx1, raises serious questions about corporate governance and fiduciary duty. The situation reflects broader industry challenges where biotech companies, particularly those with failed trials, face immense pressure to secure capital, sometimes at the expense of existing shareholder value. Lynx1's actions, including the nomination of independent directors, are typical of activist investors seeking to influence company strategy and protect shareholder interests.

Comparison to Industry Standards

• Issuing new equity at an average net proceeds of approximately $5 per share, which is less than the Company's cash value per share of $5.79, is highly unusual and generally considered poor financial management, as it directly transfers value from existing shareholders to new investors at a discount.
• Conducting a 'reckless share-issuance spree' (over 125% increase in shares outstanding in a short period) while simultaneously undergoing a strategic review is counter to best practices, as it complicates valuation and reduces the per-share value achievable in any potential sale transaction.
• Setting a record date for an annual meeting (October 15) that effectively disenfranchises a majority of current shareholders (over 55% who bought after October 20) is a highly questionable corporate governance practice and can be perceived as an act of entrenchment by the current board, deviating from principles of fair shareholder representation.
• The rapid dilution (30% per week) is an extreme measure not typically seen in well-managed companies unless under severe distress and with clear communication of necessity and strategy, which Lynx1 argues is lacking here.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders (Existing):** Face significant dilution (over 125% increase in shares outstanding) and value destruction as new shares are issued below cash value per share. Many recent shareholders may be disenfranchised from voting in the upcoming annual meeting due to the record date.
• **Shareholders (New):** May have acquired shares at a discounted price relative to the Company's cash value per share, potentially benefiting from the dilution of existing shareholders.
• **Board of Directors/Management:** Under intense pressure from an activist investor, facing accusations of 'reckless' and 'irresponsible' actions, and potential challenges to their positions through director nominations.
• **Potential Acquirers:** The withdrawal of Lynx1's offer indicates that the Company's rapidly changing capital structure makes valuation and acquisition difficult, potentially deterring other interested parties.

Next Steps

• Lynx1 calls upon the Board to commit not to undertake any further dilutive financing transactions prior to the annual meeting.
• Lynx1 demands the Board reset the record date for the annual meeting to a more current date to ensure all shareholders have a meaningful voice.
• Lynx1 has nominated two individuals, Stephen Doberstein and Kimberly Smith, for election to Neuphoria's Board of Directors.
• Lynx1 is prepared to take 'any and all actions' deemed necessary to protect the shareholders of the Company.

Key Dates

Recommendation

The filing reveals severe negative developments for Neuphoria Therapeutics. The withdrawal of a non-binding acquisition offer removes a significant potential upside. More critically, the company's 'reckless share-issuance spree' has led to over 125% dilution, with shares issued at prices below the company's cash value per share, effectively transferring value from existing shareholders. Management's actions are described as 'illogical and counterproductive' and 'acts of entrenchment,' further eroding confidence in their ability to manage the company's strategic review effectively. The disenfranchisement of a majority of current shareholders through the record date issue highlights severe corporate governance concerns. These factors collectively point to significant ongoing value destruction and a highly uncertain future, warranting a strong sell recommendation for existing shareholders.

Keywords

Neuphoria Therapeutics, Lynx1 Capital Management, Schedule 13D, Shareholder Activism, Acquisition Offer, Equity Dilution, ATM Offering, Corporate Governance, Strategic Review, Biotechnology, Board Nomination